Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®
Launched in 2016
A new drug under "Category 1 Preventative Biological Products", and the first of its kind in the world, is being developed, marking a milestone in the transformation of Chinese vaccines from "Made in China" to "Created by China”
Rapid onset of the vaccine can be achieved, as well as wide coverage for the population aged 6 to 71 months; a 2-dose inoculation grants at least 5 years of protection
Quick effect: the seroconversion rate reaches 89.2% ten days after the first injection to ensure quick protection
China has seen a significant drop in the number of severe cases and deaths from HFMD after large-scale vaccination campaigns.
Abundant studies evidence of simultaneous vaccination: the Inlive vaccine can be co-administered with hepatitis B vaccine, MCV, MMR vaccine and JE vaccine
Shelf life of 3 years and preservatives free